Form 4 for EW Edwards Lifesciences

Accepted 2023-05-15 00:00:00 ET · period of report 2023-05-11 · accession 0001225208-23-005917 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-05-15	2023-05-11	EW	Lemercier Jean-Luc M	CVP, EMEACLA, JAPAC	A - Grant	$0.00	+1,575	173.7K	+0.9%	$0
DM	2023-05-15	2023-05-11	EW	Lemercier Jean-Luc M	CVP, EMEACLA, JAPAC	A - Grant	$0.00	+15.3K	13.3K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-05-11	A	A	1,575	$0.00	173,664.78	D	—	—	(F1) These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
2	Derivative	Performance Rights	2023-05-11	A	A	1,975	$0.00	1,975	D	— · 2026-05-11 to —	1,975 Common Stock	(F3) Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.
3	Derivative	Employee Stock Option (Right to Acquire)	2023-05-11	A	A	13,300	$0.00	13,300	D	$88.78 · 2024-05-11 to 2030-05-10	13,300 Common Stock	(F2) These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.